Novel Platform of Human Respiratory Tract


Through our platforms we offer comprehensive and personalized virology services and counselling at the cutting edge of science for academia and industry specializing in infectious diseases.

  • Novel Platform of Human Respiratory Tract 0
  • Novel Platform of Human Respiratory Tract 1
  • Novel Platform of Human Respiratory Tract 2
Commercialisation opportunities
Technology licensing agreement, service providing
Problem addressed

In an effort to face the challenges posed by infectious diseases affecting respiratory tracts, we have developed comprehensive and personalized virology platforms for risk assessment and evaluation of therapeutic strategies.

  • Risk assessment of newly emerging respiratory viruses through in vitro, in vivo and ex vivo assays specific for influenza viruses and coronaviruses.
  • Development of viral infected ex-vivo and organoid models for various respiratory viruses (influenza viruses and coronaviruses) to help evaluate the efficacity of antiviral drugs and compounds, and Respiratory Organoid Platform (ROP) for personalized risk assessment.
  • Offering platforms for testing diagnostics, therapeutics, antiviral products, and vaccines as well as personalized platforms of human respiratory tract.
Key impact
  • The technology developed offers performant risk assessment through noninvasive procedure. A simple nose swab can predict infectivity of emerging respiratory viruses and host response as well as evaluate treatment responses and the development of personalized medicine.
  • The development of personalized platforms initiates the next generation of public health strategies through precision medicine.
  • Risk assessment by in vitro, in vivo and ex vivo assays and development of ex-vivo and organoid models offer a vast array of strategies and flexibility in patient care.
  • Public Health Management
  • Clinical application


  • Patents filed

Centre for Immunology & Infection

Addressing Public Health Issues Posed by Emerging Infectious Diseases

The rise of infectious diseases poses a significant threat to human health and public health systems globally. With the objective of deepening the understanding of human response to viruses and diseases, the Centre for Immunology & Infection (C2i) will contribute to establishing Hong Kong as a global centre of excellence for precision medicine tailored to population strategies and formulate innovative solutions for public health challenges with special attention to emerging infectious diseases.

A major focus of C2i is to apply a new technology platform established by the Institut Pasteur to develop an Immune Report Card for individuals, which will help define the health of one’ s immune system — the first line defence mechanism against diseases. The work will take into consideration individual genetics, previous infection histories, resident microbiota, as well as personal lifestyle and environmental factors to come up with personalised patient management strategies and improve the effectiveness of future public health initiatives.